On Friday, CytomX Therapeutics Inc (NASDAQ: CTMX) opened lower -9.00% from the last session, before settling in for the closing price of $1.00. Price fluctuations for CTMX have ranged from $0.98 to $5.85 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 28.25% over the past five years. Company’s average yearly earnings per share was noted -881.57% at the time writing. With a float of $76.93 million, this company’s outstanding shares have now reached $78.26 million.
Let’s look at the performance matrix of the company that is accounted for 122 employees. In terms of profitability, gross margin is 98.88%, operating margin of 5.3%, and the pretax margin is 11.89%.
CytomX Therapeutics Inc (CTMX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of CytomX Therapeutics Inc is 1.69%, while institutional ownership is 72.41%. The most recent insider transaction that took place on Aug 20 ’24, was worth 5,139. In this transaction Chief Business Officer of this company sold 4,181 shares at a rate of $1.23, taking the stock ownership to the 119,056 shares. Before that another transaction happened on Aug 20 ’24, when Company’s SVP, Chief Scientific Officer sold 4,181 for $1.23, making the entire transaction worth $5,139. This insider now owns 175,648 shares in total.
CytomX Therapeutics Inc (CTMX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -881.57% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.90% during the next five years compared to 67.21% growth over the previous five years of trading.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Check out the current performance indicators for CytomX Therapeutics Inc (CTMX). In the past quarter, the stock posted a quick ratio of 1.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.17, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.50 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
CytomX Therapeutics Inc (NASDAQ: CTMX) saw its 5-day average volume 1.17 million, a negative change from its year-to-date volume of 2.53 million. As of the previous 9 days, the stock’s Stochastic %D was 21.20%. Additionally, its Average True Range was 0.07.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 0.00%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.17% in the past 14 days, which was higher than the 56.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1207, while its 200-day Moving Average is $1.6026. Nevertheless, the first resistance level for the watch stands at $0.9787 in the near term. At $1.0475, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.0818. If the price goes on to break the first support level at $0.8756, it is likely to go to the next support level at $0.8413. The third support level lies at $0.7725 if the price breaches the second support level.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
There are currently 78,259K shares outstanding in the company with a market cap of 64.81 million. Presently, the company’s annual sales total 101,210 K according to its annual income of -570 K. Last quarter, the company’s sales amounted to 33,430 K and its income totaled 5,740 K.
